Long-Term Impact of Roux-en-Y Gastric Bypass on Comorbidity and Type 2 Diabetes in Adolescents: A Systematic Review and Meta-Analysis

Baraa Saad; Kenan Rahima; Mohammed Mourad; Dilip Vankayalapati; Omotayo Segun-Omosehin; Hafsa Sulaiman; James Burns; Hayato Nakanishi; Christian Than; Akheel Syed; Bilal Alkhaffaf

doi:10.1530/endoabs.117.P148

P148

Prev Next

Section Contents Cite

Endocrine Abstracts (2026) 117 P148 | DOI: 10.1530/endoabs.117.P148

SFEBES2026 Poster Presentations Metabolism, Obesity and Diabetes (68 abstracts)

Long-Term Impact of Roux-en-Y Gastric Bypass on Comorbidity and Type 2 Diabetes in Adolescents: A Systematic Review and Meta-Analysis

Baraa Saad ¹ , Kenan Rahima ² , Mohammed Mourad ³ , Dilip Vankayalapati ⁴ , Omotayo Segun-Omosehin ³ , Hafsa Sulaiman ⁵ , James Burns ⁶ , Hayato Nakanishi ⁷ , Christian Than ⁸ , Akheel Syed ^9,10 & Bilal Alkhaffaf ^9,10

Author affiliations

¹Royal Lancaster Infirmary, Lancaster, United Kingdom; ²Good Samaritan Hospital, Cincinnati, USA; ³St George’s University of London, London, United Kingdom; ⁴John Radcliffe Hospital, Oxford, United Kingdom; ⁵Cleveland Clinic, Cleveland, USA; ⁶Manchester University NHS Foundation Trust, Manchester, United Kingdom; ⁷Mayo Clinic, Rochester, USA; ⁸The University of Queensland, Brisbane, Australia; ⁹Salford Royal Hospital, Greater Manchester, United Kingdom; ¹⁰The University of Manchester, Manchester, United Kingdom

Background: The long-term impact of Roux-en-Y gastric bypass (RYGB) on comorbidities in adolescents with severe obesity remains incompletely defined. We conducted a systematic review and meta-analysis to evaluate remission of type 2 diabetes (T2DM), hypertension, and dyslipidaemia after RYGB in this population.

Methods: Searches of MEDLINE, EMBASE, Cochrane, and SCOPUS were performed to July 2023. Eligible studies included patients under 21 years undergoing RYGB with ≥2 years of follow-up. Data were pooled using a random-effects model. Primary outcomes were remission of T2DM, dyslipidaemia, and hypertension.

Results: Twelve studies comprising 522 adolescents were included. The mean age was 17.5 years (range 13–21), and 73.6% were female. Mean follow-up duration was 48.4 months. Baseline mean body mass index (BMI) was 50.1 kg/m². Preoperatively, 12.2% had established T2DM, 24.3% had hypertension, and 29.7% of patients had dyslipidaemia. T2DM remission was achieved in 85% of patients, with 73% remission of hypertension and 85% remission of dyslipidaemia.

Conclusion: RYGB in adolescents with severe obesity results in substantial remission of type 2 diabetes and obesity associated comorbidities. While metabolic outcomes are favourable, the risk of postoperative complications must also be considered. Further long-term longitudinal studies extending into late adulthood are needed.